minoxidil / Generic mfg. - LARVOL DELTA

BH15 Nonsyndromic hypotrichosis: a rare case of congenital hypotrichosis 15 and management with minoxidil. (PubMed, Br J Dermatol) - "Our case also confirms that the changes in the C3orf52 gene leading to congenital hypotrichosis are caused by null alleles (no expected protein expression). In all reported cases, the C3orf52 gene abnormality was present in the homozygous state, corresponding with the extreme rarity of this condition."

Journal

O04 Pharmacological efficacy of low-dose oral minoxidil-finasteride combination for hair growth and stability in male androgenetic alopecia: a 12-month retrospective service evaluation. (PubMed, Br J Dermatol) - "Nonetheless, modest κ-values reinforce the necessity for objective imaging protocols or artificial intelligence-driven methods in future research. Prospective, controlled trials incorporating explicit safety monitoring and patient-reported outcomes are warranted to optimize dosing and validate long-term tolerability."

Journal • Retrospective data • Alopecia • Immunology

Botanical drug preparations for alleviating hair loss in menopausal women: a global ethnopharmacological mini-review. (PubMed, Front Pharmacol) - "Conventional treatments like minoxidil provide limited efficacy and may cause side effects, underscoring the need for accessible, culturally attuned alternatives...It advocates for future priorities like interdisciplinary trials integrating ethnobotany with modern pharmacology to bridge global health disparities. This aligns with the special issue's vision of empowering women through sustainable, nature-based solutions."

Journal • Review • Alopecia

BH27 When patterns blur: recognizing the overlap of alopecia areata and lichen planopilaris. (PubMed, Br J Dermatol) - "Treatments to date have included triamcinolone injections, oral hydroxychloroquine and oral minoxidil, with some symptomatic relief and clinical improvement. This case emphasizes the importance of recognizing the overlap between alopecia areata and lichen planopilaris, which are rarely documented together, as well as the necessity for a comprehensive clinical and histological evaluation in atypical presentations of hair loss. The report contributes to the limited literature on this dual diagnosis and may guide future clinical management strategies for similar cases."

Journal • Alopecia • Dermatology • Fibrosis • Immunology • Inflammation • Lichen Planus

BH20 A multicentre analysis of the adequacy of alopecia horizontal biopsy samples over 10 years. (PubMed, Br J Dermatol) - "Twenty-six patients had received either topical steroids, minoxidil, spironolactone, tamoxifen, contraceptive pill, azathioprine or ketoconazole shampoo. We recommend using a standardized alopecia request form with clinical data and duration of onset, avoiding biopsies for very early or very late-onset disease of > 4 years, and inserting a follicular analysis table within the report to compare with the normal standard values, to improve the diagnostic outcome. Combining the use of digital pathology with artificial intelligence in the future may increase the diagnostic accuracy."

Journal • Retrospective data • Acne Vulgaris • Alopecia • Atopic Dermatitis • Breast Cancer • Chronic Kidney Disease • CNS Disorders • Crohn's disease • Depression • Dermatology • Dermatomyositis • Dermatopathology • Diabetes • Endocrine Disorders • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Lupus • Metabolic Disorders • Mood Disorders • Multiple Sclerosis • Myositis • Oncology • Polycystic Ovary Syndrome • Psoriasis • Psychiatry • Renal Disease • Rheumatology • Sjogren's Syndrome • Solid Tumor • Systemic Lupus Erythematosus • Urticaria

BH04 Growing interest: a survey of low-dose oral minoxidil prescribing for hair loss. (PubMed, Br J Dermatol) - "For female pattern hair loss, 90% (n = 26) would prescribe LDOM as monotherapy and 66% (n = 19) would use it with spironolactone. For FFP/LPP, 79% (n = 23) would not prescribe LDOM as monotherapy, but would use it as an adjunct, most commonly with hydroxychloroquine (n = 20), followed by tetracyclines (n = 19)...Our study highlights the variation in LDOM prescribing within the UK and Ireland. It demonstrates the wide use of LDOM by dermatologists both as an adjunct and as monotherapy for a wide range of hair loss conditions."

Journal • Alopecia • Fibrosis • Immunology • Lichen Planus

Response to Olsen et al's ''Summation and recommendations for the safe and effective use of topical and oral minoxidil". (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Alopecia • Cardiovascular • Immunology

Engineered collagen XVII-loaded dissolving microneedle patch for promoting hair regrowth in androgenic alopecia. (PubMed, Regen Biomater) - "Current therapies, such as minoxidil, are limited by poor patient compliance and low transdermal bioavailability, highlighting the need for more effective treatments...The rhCOL17p-MN also demonstrated low hemolysis (<0.5%) and robust mechanical stability (≥0.2 N/needle), confirming its safety and feasibility. These findings establish COL17 downregulation as a critical mechanism in AGA and demonstrate that MN-delivered rhCOL17p promotes hair regeneration through multi-pathway regulation, offers preclinical evidence supporting its potential as a candidate strategy for further investigation in AGA-related research."

Journal • Alopecia • Hematological Disorders • Immunology • CD31 • CTNNB1 • PECAM1 • SOX9

mina: Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia (clinicaltrials.gov) - P3 | N=200 | Not yet recruiting | Sponsor: Sheikh Zayed Federal Postgraduate Medical Institute

New P3 trial • Alopecia • Dermatology • Immunology

Response to Neubauer et al., "No association between low dose oral minoxidil and tachycardia in a large retrospective cohort study of non-scarring alopecia patients". (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Retrospective data • Alopecia • Cardiovascular • Dermatology • Immunology

Minoxidil's Pulse Check. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Alopecia • Cardiovascular • Hypotension • Immunology

Targeting sonic hedgehog (shh) signaling pathways by the concentration-dependent topical resveratrol for protection from cyclophosphamide-induced alopecia in a mouse model. (PubMed, Toxicol Appl Pharmacol) - "Topical low-dose resveratrol protects against CIA by activating Shh signaling and modulating follicular proliferative and apoptotic pathways."

IO biomarker • Journal • Preclinical • Alopecia • Immunology • Oncology • BCL2 • CASP3

Photobiomodulation therapy and 5% minoxidil in female pattern hair loss: a case series focusing on hair growth phases over a shorter timeframe. (PubMed, Lasers Med Sci) - "These findings suggest that PBMt may enhance MIN therapy for FPHL, particularly in reducing telogen-phase hair counts within a shorter treatment period."

Clinical • Journal • Alopecia • Immunology

Combined Low Dose Oral Minoxidil and Immunomodulator Efficacy and Safety in Alopecia Areata: A Systematic Review. (PubMed, Int J Dermatol) - No abstract available

Journal • Alopecia • Immunology

Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia (clinicaltrials.gov) - P3 | N=190 | Recruiting | Sponsor: EMS | Trial completion date: Sep 2025 ➔ Sep 2027 | Trial primary completion date: Apr 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

The Requirement to Monitor Low-dose Oral Minoxidil in the Management of Hair Loss. (PubMed, Int J Trichology) - "Patients with preexisting renal impairment can be prescribed oral minoxidil; however, we advocate ongoing monitoring in this subgroup, especially those with moderate-to-advanced disease. To the best of our knowledge, this is the first study that provides longitudinal monitoring data for LDOM with a follow-up period beyond 6 months and up to 36 months on treatment."

Journal • Alopecia • Renal Disease

Characteristics of Hypertrichosis Induced by 24-week Low-dose (5 mg Daily) Oral Minoxidil in Male Pattern Hair Loss Treatment. (PubMed, Int J Trichology) - "The 24-week treatment of low-dose 5 mg daily OM induces a high prevalence of hypertrichosis in male AGA patients. Further study is recommended for long-term implications and safety profiles of low-dose oral minoxidil."

Journal • Alopecia • Cardiovascular • Dermatology • Hypertension • Immunology

Omeprazole-Mediated Nanodelivery of Copper for Synchronous Remodeling of Copper Influx and Efflux in Cuproptotic Glioblastoma Therapy. (PubMed, Acta Biomater) - "To improve the permeability across blood-brain tumor barrier (BTB), minoxidil sulfate (MS) and T7 peptide are modified on Cu-OME SNDs to produce Cu-OME/MS@T7 SNDs. Meanwhile, the released OME further blocks copper efflux by suppressing ATP7A copper efflux transporter. Collectively, this work demonstrates the effectiveness of OME-mediated copper delivery in inducing copper dyshomeostasis and triggering cuproptosis, highlighting a promising therapeutic approach through synchronous remodeling of copper influx and efflux."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • ATP7A

Combination Oral Minoxidil and Baricitinib for Alopecia Areata. A retrospective study of 77 patients. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Retrospective data • Alopecia • Immunology

Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: Duke University

New P1 trial • Breast Cancer • Oncology • Solid Tumor

Amine-Functionalized Chitosan/dECM Composite Promotes Cutaneous Regeneration and Hair Follicle Activation by Regulating Oxidative Stress and Inflammation. (PubMed, Adv Healthc Mater) - "In vivo, the composite accelerated epidermal repair and hair follicle regeneration in a UVB-induced scalp injury mouse model, demonstrating superior regenerative outcomes compared with minoxidil. These results suggest that aaCMC + h-dECM is a multi-functional regenerative platform capable of restoring scalp homeostasis through the combination of ROS modulation, immune regulation, and ECM support. This strategy may provide a multi-functional therapeutic alternative to conventional monotherapies for inflammatory hair loss."

Journal • Alopecia • Inflammation • FN1

Updates in Treatment for Androgenetic Alopecia. (PubMed, Ann Dermatol) - "Topical minoxidil and oral finasteride are the most widely used treatments for AGA, addressing follicular miniaturization...Finasteride and dutasteride, both 5-α-reductase inhibitors that reduce DHT levels in hair follicles, are key androgen-targeting treatments, with newer formulations like topical and injectable options emerging alongside traditional oral forms...This review explores current and emerging treatments for AGA, addressing both androgen-targeted and non-androgen-targeted approaches with an emphasis on their mechanisms, efficacy, and safety. It ultimately aims to provide a comprehensive update on the latest advancements in AGA management."

Journal • Review • Alopecia • CNS Disorders • Immunology

Overcoming the Low Bioavailability of Apigenin: The Therapeutic Efficacy for Androgenetic Alopecia Through Topical Administration. (PubMed, Food Sci Nutr) - "After 28 days of treatment in testosterone-induced AGA mice, the hair growth status was comparable to that in the minoxidil group and the normal group, and was significantly better than that in the model group...The docking study revealed that CDK5 is the most likely target of apigenin for treating AGA. This study verified that topical administration of apigenin is a viable strategy for drug development."

Journal • Alopecia • Dermatology • Immunology • Oncology

Relevance of topical application of minoxidil laden nano-lipid for hair growth enhancement. (PubMed, Saudi Pharm J) - "The formula was stable when preserved for 12 months at both applied conditions. Finally, the formula demonstrated significant faster rate of hair growth that mostly owed to the value of nanocarrier in delivering drug into follicular hairs."

Journal • Alopecia • Cardiovascular • Dermatology • Hypertension

Short-Term Topical Minoxidil Use Associated with Acute Central Serous Chorioretinopathy: A Case Report. (PubMed, Case Rep Ophthalmol) - "This case report suggests that short-term use of topical minoxidil, as short as 1 week, can induce CSCR. Our case shows that minoxidil-induced CSCR can be managed with medication discontinuation and observation."

Journal • Alopecia • Ophthalmology • Retinal Disorders